Grading Severity of Productive Cough Based on Symptoms and Airflow Obstruction

References

• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006 28(3):523–32. doi:10.1183/09031936.06.00124605.
   PubMed Web of Science ®Google Scholar
• Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1–120.
   PubMed Web of Science ®Google Scholar
• de Oca MM, Halbert RJ, Lopez MV, Perez-Padilla R, Tálamo C, Moreno D, Muiño A, Jardim JR, Valdivia G, Pertuzé J. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012;40(1):28–36. doi:10.1183/09031936.00141611.
   PubMed Web of Science ®Google Scholar
• Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, Burney P, de Marco R, European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J. 2001;18(1):85–92. doi:10.1183/09031936.01.00087101.
   PubMed Web of Science ®Google Scholar
• Lu M, Yao W, Zhong N, Zhou Y, Wang C, Chen P, Kang J, Huang S, Chen B, Wang C. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology. 2010;15(7):1072–8. doi:10.1111/j.1440-1843.2010.01817.x.
   PubMed Web of Science ®Google Scholar
• Meek PM, Petersen H, Washko GR, Diaz AA, Kim V, Sood A, et al. Chronic Bronchitis Is Associated With Worse Symptoms and Quality of Life Than Chronic Airflow Obstruction. Chest. 2015;148(2):408–16. doi:10.1378/chest.14-2240.
   PubMed Web of Science ®Google Scholar
• Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. Am J Respir Crit Care Med. 2016;193(6):662. doi:10.1164/rccm.201511-2210OC.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med. 2016;374(19):1811–21. doi:10.1056/NEJMoa1505971.
   PubMed Web of Science ®Google Scholar
• Pelkonen M, Notkola I-L, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006;130(4):1129–37. doi:10.1378/chest.130.4.1129.
   PubMed Web of Science ®Google Scholar
• Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999;106(4):410–6. doi:10.1016/S0002-9343(99)00056-X.
   PubMed Web of Science ®Google Scholar
• Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegte IG a. T, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26(5):835–45. doi:10.1183/09031936.05.00108904.
   PubMed Web of Science ®Google Scholar
• Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal Airway Inflammation in Chronic Bronchitis: Characterization and Correlation with Clinical Parameters. Am Rev Respir Dis. 1989;140(6):1527–37. doi:10.1164/ajrccm/140.6.1527.
   PubMedGoogle Scholar
• Reid L. PATHOLOGY OF CHRONIC BRONCHITIS. The Lancet. 1954;263(6806):275–8. doi:10.1016/S0140-6736(54)91030-2.
   Google Scholar
• Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46(8):798–825.
   PubMedGoogle Scholar
• Mannino DM. Gold stage 0 copd: Is it real? does it matter? Chest. 2006;130(2):309–10. doi:10.1016/S0012-3692(15)51839-4.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Lange P. Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2002;166(3):329–32. doi:10.1164/rccm.2112048.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary | European Respiratory Society [Internet]. [cited 2017 Feb 27]. Available from: http://erj.ersjournals.com.libproxy.unm.edu/content/early/2017/01/30/13993003.00214-2017.1
   Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(5 Pt 2):S77–121.
   PubMed Web of Science ®Google Scholar
• Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373(2):111–22. doi:10.1056/NEJMoa1411532.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145(4):695–703. doi:10.1378/chest.13-0799.
   PubMed Web of Science ®Google Scholar
• Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, Tesfaigzi Y. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med. 2010;182(9):1098–104. doi:10.1164/rccm.201002-0222OC.
   PubMed Web of Science ®Google Scholar
• Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic Epidemiology of COPD (COPDGene) Study Design. COPD. 2010;7(1):32–43. doi:10.3109/15412550903499522.
   PubMedGoogle Scholar
• Petersen H, Leng S, Belinsky SA, Miller BE, Tal-Singer R, Owen CA, Celli B, Tesfaigzi Y. Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. Eur Respir J. 2015;46(5):1501–3. doi:10.1183/13993003.00682-2015.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Mannino DM, Yawn BP, Mapel DW, Martinez FJ, Donohue JF, Kosinski M, Rendas-Baum R, Mintz M, Samuels S. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010;104(8):1160–70. doi:10.1016/j.rmed.2010.02.009.
   PubMed Web of Science ®Google Scholar
• Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet Lond Engl. 2008;371(9621):1364–74. doi:10.1016/S0140-6736(08)60595-4.
   PubMed Web of Science ®Google Scholar
• Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther. 2000;22(9):1121–45.
   Google Scholar
• McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JFR. The Validity and Relative Precision of MOS Short- and Long-Form Health Status Scales and Dartmouth COOP Charts: Results from the Medical Outcomes Study. Med Care. 1992;30(5):MS253–65. PMID:1583937.
   PubMed Web of Science ®Google Scholar
• Sood A, Petersen H, Qualls C, Meek PM, Vazquez-Guillamet R, Celli BR, Tesfaigzi Y. Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respir Res. 2016;17:147. doi:10.1186/s12931-016-0468-7. PMID:27832774.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–8. doi:10.1136/bmj.1.6077.1645.
   PubMed Web of Science ®Google Scholar
• Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects: the Tucson Study. Eur Respir J. 1993;6(3):342–8.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53. doi:10.1056/NEJMoa032158.
   PubMed Web of Science ®Google Scholar
• Accordini S, Corsico AG, Cerveri I, Antonicelli L, Attena F, Bono R, Casali L, Ferrari M, Fois A, Marchetti P. Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010. Respir Res. 2013;14:16. doi:10.1186/1465-9921-14-16.
   PubMed Web of Science ®Google Scholar
• Meteran H, Backer V, Kyvik KO, Skytthe A, Thomsen SF. Heredity of chronic bronchitis: a registry-based twin study. Respir Med. 2014;108(9):1321–6. doi:10.1016/j.rmed.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Ferré A, Fuhrman C, Zureik M, Chouaid C, Vergnenègre A, Huchon G, et al. Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. Respir Med. 2012;106(3):467–71. doi:10.1016/j.rmed.2011.12.002.
   PubMed Web of Science ®Google Scholar
• Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, et al. Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012;186(12):1238–47. doi:10.1164/rccm.201206-1013OC.
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Polverino F, Gupta K, Taylor KL, Kelly E, Pinto-Plata V, Divo M, Ashfaq N, Petersen H, Stripp B. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir J. 2015;45(6):1544–56. doi:10.1183/09031936.00134214.
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–33. doi:10.1378/chest.10-2948.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet Lond Engl. 2015;385(9971):857–66. doi:10.1016/S0140-6736(14)62410-7.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007;356(8):775–89. doi:10.1056/NEJMoa063070.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54. doi:10.1056/NEJMoa0805800.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34. doi:10.1056/NEJMoa1516385. PMID:27181606.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Tan WC, Bourbeau J, Sin DD, Loves RH, MacNeil J, Whitmore GA, Canadian Respiratory Research Network. Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. Am J Respir Crit Care Med. 2017;196(3):306–14. doi:10.1164/rccm.201612-2531OC.
   PubMed Web of Science ®Google Scholar
• Vazquez Guillamet R, Petersen H, Meek PM, Tesfaigzi Y, Sood A. Normalization of FEV1/FVC Ratio to >0.7 Does Not Equal Resolution of Disease. Am J Respir Crit Care Med. 2018;197(6):834–835. doi:10.1164/rccm.201708-1693LE.
   PubMed Web of Science ®Google Scholar